The Relationships Between the Noradrenergic, Opioid and Pain System
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist
研究概览
简要总结
The role of alpha2 receptor agonist on pain perception and modulation will be examined. In addition whether this is mediated through the opioid system will be examined. Pain perception and modulation will be examined before and after administration of Clonidine or placebo together with Naloxone or saline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers
- •Age 18-40
- •No chronic disease
排除标准
- •Subjects who suffer from chronic pain / pain syndrome
- •use of anti-depressant or anti-psychotic drugs
- •suffering from cardiovascular disease
- •breast feeding
研究组 & 干预措施
Placebo +saline
Placebo 0.15 mg+ saline 0.15 mg/kg
干预措施: placebo (Drug)
Placebo +saline
Placebo 0.15 mg+ saline 0.15 mg/kg
干预措施: saline (Other)
Clonidine+ Saline
Clonidine 0.15 mg and saline 0.15 mg/kg
干预措施: Clonidine (Drug)
Clonidine+ Saline
Clonidine 0.15 mg and saline 0.15 mg/kg
干预措施: saline (Other)
Clonidine + Naloxone
Clonidine 0.15 mg and Naloxone 0.15 mg/kg
干预措施: Clonidine (Drug)
Clonidine + Naloxone
Clonidine 0.15 mg and Naloxone 0.15 mg/kg
干预措施: Naloxone (Drug)
Placebo +Naloxone
Placebo 0.15 mg+ naloxone 0.15 mg/kg
干预措施: Naloxone (Drug)
Placebo +Naloxone
Placebo 0.15 mg+ naloxone 0.15 mg/kg
干预措施: placebo (Drug)
结局指标
主要结局
The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist
时间窗: 2 years
The change in pain perception (pain thresholds and pain ratings of suprathresholds stimuli) and in the excitatory and inhibitory pain modulation responses (assessed by the temporal summation and conditioned pain modulation paradigms) will be examined before and after administration of alpha 2 agonist with and without mu receptor antagonist
次要结局
未报告次要终点
研究者
d_yarnitsky
Professor, Head on Neurology Department
Rambam Health Care Campus